This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Five Prime Therapeutics, Inc.
Drug Names(s): FPA-144
Description: FPA144 is an anti-fibroblast growth factor receptor 2 (FGFR2) receptor 2b humanized monoclonal antibody. FPA144 is designed to inhibit tumor growth by preventing the binding of certain fibroblast growth factors to FGF receptor 2b (FGFR2b) and directly kill tumor cells in a process called antibody-dependent cell-mediated cytotoxicity (ADCC).
Additional information available to subscribers only: